Cargando…

Near‐normalization of glycaemic control with glucagon‐like peptide‐1 receptor agonist treatment combined with exercise in patients with type 2 diabetes

AIMS: To investigate the effects of exercise in combination with a glucagon‐like peptide‐1 receptor agonist (GLP‐1RA), liraglutide, or placebo for the treatment of type 2 diabetes. METHODS: Thirty‐three overweight, dysregulated and sedentary patients with type 2 diabetes were randomly allocated to 1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mensberg, P., Nyby, S., Jørgensen, P. G., Storgaard, H., Jensen, M. T., Sivertsen, J., Holst, J. J., Kiens, B., Richter, E. A., Knop, F. K., Vilsbøll, T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2016
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5298031/ https://www.ncbi.nlm.nih.gov/pubmed/27717126 http://dx.doi.org/10.1111/dom.12797

Ejemplares similares

How glucagon-like peptide 1 receptor agonists work
por: Andreasen, Christine Rode, et al.
Publicado: (2021)

Effects of glucagon‐like peptide‐1 receptor agonists on cardiovascular risk factors: A narrative review of head‐to‐head comparisons
por: Dalsgaard, Niels B., et al.
Publicado: (2017)

The Glucagonostatic and Insulinotropic Effects of Glucagon-Like Peptide 1 Contribute Equally to Its Glucose-Lowering Action
por: Hare, Kristine J., et al.
Publicado: (2010)

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials
por: Vilsbøll, Tina, et al.
Publicado: (2012)

Unprecedented high insulin secretion in a healthy human subject after intravenous glucagon-like peptide-1: a case report
por: Knop, Filip K, et al.
Publicado: (2014)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

A glucose-insulin-glucagon coupled model of the isoglycemic intravenous glucose infusion experiment
por: Subramanian, Vijaya, et al.
Publicado: (2022)

Glucose-Dependent Insulinotropic Polypeptide: A Bifunctional Glucose-Dependent Regulator of Glucagon and Insulin Secretion in Humans
por: Christensen, Mikkel, et al.
Publicado: (2011)

The effect of a glucagon-like peptide-1 receptor agonist on glucose tolerance in women with previous gestational diabetes mellitus: protocol for an investigator-initiated, randomised, placebo-controlled, double-blinded, parallel intervention trial
por: Foghsgaard, Signe, et al.
Publicado: (2013)

Acyl‐CoA synthetase expression in human skeletal muscle is reduced in obesity and insulin resistance
por: Poppelreuther, Margarete, et al.
Publicado: (2023)

Inability of Some Commercial Assays to Measure Suppression of Glucagon Secretion
por: Wewer Albrechtsen, Nicolai J., et al.
Publicado: (2016)

The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition
por: Hædersdal, Sofie, et al.
Publicado: (2020)

Glucagon-Like Peptide 2 Inhibits Postprandial Gallbladder Emptying in Man: A Randomized, Double-Blinded, Crossover Study
por: Hansen, Nina L., et al.
Publicado: (2020)

The Effect of Glucagon-Like Peptide-2 Receptor Agonists on Colonic Anastomotic Wound Healing
por: Redstone, Heather A., et al.
Publicado: (2010)

Glucagon Receptor Signaling and Glucagon Resistance
por: Janah, Lina, et al.
Publicado: (2019)

Stability of glucagon-like peptide 1 and glucagon in human plasma
por: Wewer Albrechtsen, Nicolai J, et al.
Publicado: (2015)

One Year’s Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial
por: Vedtofte, Louise, et al.
Publicado: (2020)

Glucagon Receptor Signaling and Lipid Metabolism
por: Galsgaard, Katrine D., et al.
Publicado: (2019)

Glucagon-like peptide-1 receptor agonists in patients treated with antipsychotics
por: Delgado, A., et al.
Publicado: (2021)

Protocol for a randomised, double-blinded, placebo-controlled, double-dummy 6-week clinical trial comparing the treatment effects of the glucagon-like peptide 1 receptor agonist liraglutide versus the bile acid sequestrant colesevelam on bile acid malabsorption
por: Kårhus, Martin Lund, et al.
Publicado: (2021)

Mechanisms of the Incretin Effect in Subjects with Normal Glucose Tolerance and Patients with Type 2 Diabetes
por: Mari, Andrea, et al.
Publicado: (2013)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017)

Real‐world evidence of the effectiveness on glycaemic control of early simultaneous versus later sequential initiation of basal insulin and glucagon‐like peptide‐1 receptor agonists
por: Rosenstock, Julio, et al.
Publicado: (2020)

Transitioning from basal–bolus or premix insulin therapy to a combination of basal insulin and glucagon‐like peptide‐1 receptor agonist in people with type 2 diabetes
por: Mehta, Roopa, et al.
Publicado: (2022)

Roles of increased glycaemic variability, GLP-1 and glucagon in hypoglycaemia after Roux-en-Y gastric bypass
por: Tharakan, George, et al.
Publicado: (2017)

Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
por: Kang, Yu Mi, et al.
Publicado: (2016)

Glucagon and other proglucagon-derived peptides in the pathogenesis of obesity
por: Holst, Jens Juul
Publicado: (2022)

In vivo and in vitro characterization of GL0034, a novel long‐acting glucagon‐like peptide‐1 receptor agonist
por: Jones, Ben, et al.
Publicado: (2022)

Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease
por: Baggio, Laurie L., et al.
Publicado: (2020)

GIP and GLP-1 Potentiate Sulfonylurea-Induced Insulin Secretion in Hepatocyte Nuclear Factor 1α Mutation Carriers
por: Christensen, Alexander S., et al.
Publicado: (2020)

Glucagon-Like Peptide-1 Receptor Agonist Treatment Does Not Reduce Abuse-Related Effects of Opioid Drugs
por: Bornebusch, Annika Billefeld, et al.
Publicado: (2019)

Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density
por: Eriksson, Robert, et al.
Publicado: (2019)

Synthesis and biological evaluation of glucagon-like peptide-1 receptor agonists
por: Zhang, Yu-Juan, et al.
Publicado: (2013)

Glucagon‐like peptide‐1 receptor agonists and their effects on weight reduction
por: Shin, Shyi‐Jang
Publicado: (2012)

Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
por: Hinnen, Deborah
Publicado: (2017)

The potential of glucagon-like peptide-1 receptor agonists in heart failure
por: Kreiner, Frederik Flindt, et al.
Publicado: (2022)

Glucagon-Like Peptide-1 Receptor Agonists for Chronic Weight Management
por: Wojtara, Magda, et al.
Publicado: (2023)

Effect of bile acid sequestrants on glycaemic control: protocol for a systematic review with meta-analysis of randomised controlled trials
por: Hansen, Morten, et al.
Publicado: (2012)

Glucagon-like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth
por: Berman, Casey, et al.
Publicado: (2023)

Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance
por: Almandoz, Jaime P., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rlohaettgek6ue2pdklfli7j34